Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Thomas Campbell to HIV-1

This is a "connection" page, showing publications Thomas Campbell has written about HIV-1.

 
Connection Strength
  
 
 
4.257
  
  1. Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W, Infante R, Rana A, Kumarasamy N, Hakim J, Campbell TB. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015 May-Jun; 16(3):89-99.
    View in: PubMed
    Score: 0.287
  2. Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, Wilson CC, MaWhinney S, Kohrt WM, Campbell TB. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013 Jul 15; 208(2):249-59.
    View in: PubMed
    Score: 0.248
  3. Erlandson KM, Allshouse AA, Jankowski CM, Duong S, Mawhinney S, Kohrt WM, Campbell TB. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials. 2012 Nov-Dec; 13(6):324-34.
    View in: PubMed
    Score: 0.241
  4. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012; 9(8):e1001290.
    View in: PubMed
    Score: 0.237
  5. Safren SA, Hendriksen ES, Smeaton L, Celentano DD, Hosseinipour MC, Barnett R, Guanira J, Flanigan T, Kumarasamy N, Klingman K, Campbell T. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS Behav. 2012 Feb; 16(2):266-77.
    View in: PubMed
    Score: 0.229
  6. Campbell TB. Are all HIV type 1 strains created equal? Clin Infect Dis. 2006 Mar 15; 42(6):853-4.
    View in: PubMed
    Score: 0.151
  7. Campbell TB, Rapaport E, Schooley RT, Kuritzkes DR. Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. J Infect Dis. 2004 Jul 15; 190(2):257-66.
    View in: PubMed
    Score: 0.135
  8. Campbell TB, Schneider K, Wrin T, Petropoulos CJ, Connick E. Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol. 2003 Nov; 77(22):12105-12.
    View in: PubMed
    Score: 0.129
  9. Letendre SL, Chen H, McKhann A, Roa J, Vecchio A, Daar ES, Berzins B, Hunt PW, Marra CM, Campbell TB, Coombs RW, Ma Q, Swaminathan S, Macatangay BJC, Morse GD, Miller T, Rusin D, Greninger AL, Ha B, Alston-Smith B, Robertson K, Paul R, Spudich S. Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus. Clin Infect Dis. 2023 09 18; 77(6):866-874.
    View in: PubMed
    Score: 0.128
  10. Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, Gudza I, Fitzpatrick L, Schooley RT. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS. 2000 Sep 29; 14(14):2109-16.
    View in: PubMed
    Score: 0.104
  11. Vecchio AC, Marra CM, Schouten J, Jiang H, Kumwenda J, Supparatpinyo K, Hakim J, Sacktor N, Campbell TB, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firnhaber C, Hosseinipour MC, Mngqibisa R, Hall C, Cinque P, Robertson K. Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings. Clin Infect Dis. 2020 06 24; 71(1):158-165.
    View in: PubMed
    Score: 0.102
  12. Campbell TB, Sevin A, Coombs RW, Peterson GC, Rosandich M, Kuritzkes DR, Mladenovic J, Landay A, Wong R, Ambruso D, Miles S, Pomerantz RJ, Schooley RT. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000 Jan 01; 95(1):48-55.
    View in: PubMed
    Score: 0.099
  13. Campbell TB, Fitzpatrick L, MaWhinney S, Zhang X, Schooley RT. Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) infection in men receiving treatment for HIV-1 infection. J Acquir Immune Defic Syndr. 1999 Dec 01; 22(4):333-40.
    View in: PubMed
    Score: 0.098
  14. Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
    View in: PubMed
    Score: 0.089
  15. Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT. Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population. PLoS One. 2015; 10(6):e0129519.
    View in: PubMed
    Score: 0.072
  16. Neff CP, Chain JL, MaWhinney S, Martin AK, Linderman DJ, Flores SC, Campbell TB, Palmer BE, Fontenot AP. Lymphocytic alveolitis is associated with the accumulation of functionally impaired HIV-specific T cells in the lung of antiretroviral therapy-naive subjects. Am J Respir Crit Care Med. 2015 Feb 15; 191(4):464-73.
    View in: PubMed
    Score: 0.071
  17. Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, Morgado MG, Saravanan S, Balakrishnan P, Reitsma M, Hart S, Mellors JW, Halvas E, Grinsztejn B, Hosseinipour MC, Kumwenda J, La Rosa A, Lalloo UG, Lama JR, Rassool M, Santos BR, Supparatpinyo K, Hakim J, Flanigan T, Kumarasamy N, Campbell TB, Eshleman SH. Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. Clin Infect Dis. 2015 May 15; 60(10):1541-9.
    View in: PubMed
    Score: 0.071
  18. Touzard Romo F, Smeaton LM, Campbell TB, Riviere C, Mngqibisa R, Nyirenda M, Supparatpinyo K, Kumarasamy N, Hakim JG, Flanigan TP. Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials. 2014 Nov-Dec; 15(6):246-60.
    View in: PubMed
    Score: 0.069
  19. Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, Gulick RM, Na L, O'Keefe L, Robertson KR, Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014 Jul 01; 161(1):1-10.
    View in: PubMed
    Score: 0.068
  20. Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15; 59(6):888-96.
    View in: PubMed
    Score: 0.067
  21. Steele AK, Lee EJ, Vestal B, Hecht D, Dong Z, Rapaport E, Koeppe J, Campbell TB, Wilson CC. Contribution of intestinal barrier damage, microbial translocation and HIV-1 infection status to an inflammaging signature. PLoS One. 2014; 9(5):e97171.
    View in: PubMed
    Score: 0.067
  22. Erlandson KM, Gudza I, Fiorillo S, Ndemera B, Schooley RT, Gwanzura L, Borok M, Campbell TB. Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe. Int J Infect Dis. 2014 Jul; 24:6-10.
    View in: PubMed
    Score: 0.067
  23. Périssé AR, Smeaton L, Chen Y, La Rosa A, Walawander A, Nair A, Grinsztejn B, Santos B, Kanyama C, Hakim J, Nyirenda M, Kumarasamy N, Lalloo UG, Flanigan T, Campbell TB, Hughes MD. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease. PLoS One. 2013; 8(12):e83643.
    View in: PubMed
    Score: 0.065
  24. Campbell TB, Young RK, Eron JJ, D'Aquila RT, Tarpley WG, Kuritzkes DR. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. J Infect Dis. 1993 Aug; 168(2):318-26.
    View in: PubMed
    Score: 0.063
  25. Nelson BC, Borok MZ, Mhlanga TO, Makadzange AT, Campbell TB. AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe. Int J Infect Dis. 2013 Oct; 17(10):e902-6.
    View in: PubMed
    Score: 0.063
  26. Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013 Sep; 208(6):884-91.
    View in: PubMed
    Score: 0.063
  27. Fiscus SA, Cu-Uvin S, Eshete AT, Hughes MD, Bao Y, Hosseinipour M, Grinsztejn B, Badal-Faesen S, Dragavon J, Coombs RW, Braun K, Moran L, Hakim J, Flanigan T, Kumarasamy N, Campbell TB. Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy. Clin Infect Dis. 2013 Jul; 57(2):290-7.
    View in: PubMed
    Score: 0.062
  28. Erlandson KM, Allshouse AA, Jankowski CM, Duong S, MaWhinney S, Kohrt WM, Campbell TB. Risk factors for falls in HIV-infected persons. J Acquir Immune Defic Syndr. 2012 Dec 01; 61(4):484-9.
    View in: PubMed
    Score: 0.061
  29. Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman KL, Shapiro DE, Mofenson L, Moran L, Campbell TB, Hitti J, Fiscus S, Currier J. Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics. 2012 Jun; 129(6):e1525-32.
    View in: PubMed
    Score: 0.058
  30. Meditz AL, Haas MK, Folkvord JM, Melander K, Young R, McCarter M, Mawhinney S, Campbell TB, Lie Y, Coakley E, Levy DN, Connick E. HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol. 2011 Oct; 85(19):10189-200.
    View in: PubMed
    Score: 0.055
  31. Grinsztejn B, Smeaton L, Barnett R, Klingman K, Hakim J, Flanigan T, Kumarasamy N, Campbell T, Currier J. Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther. 2011; 16(7):1057-62.
    View in: PubMed
    Score: 0.053
  32. Firnhaber C, Smeaton L, Saukila N, Flanigan T, Gangakhedkar R, Kumwenda J, La Rosa A, Kumarasamy N, De Gruttola V, Hakim JG, Campbell TB. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis. 2010 Dec; 14(12):e1088-92.
    View in: PubMed
    Score: 0.052
  33. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509.
    View in: PubMed
    Score: 0.052
  34. Letang E, Almeida JM, Miró JM, Ayala E, White IE, Carrilho C, Bastos R, Nhampossa T, Menéndez C, Campbell TB, Alonso PL, Naniche D. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study. J Acquir Immune Defic Syndr. 2010 Apr; 53(5):589-97.
    View in: PubMed
    Score: 0.050
  35. Campbell TB, Borok M, Ndemera B, Fiorillo S, White IE, Zhang XQ, Machekano RN, Katzenstein D, Gwanzura L. Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe. Clin Infect Dis. 2009 Jun 01; 48(11):1601-8.
    View in: PubMed
    Score: 0.048
  36. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods. 2007 Dec; 146(1-2):136-46.
    View in: PubMed
    Score: 0.042
  37. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 07; 370(9581):39-48.
    View in: PubMed
    Score: 0.042
  38. Boritz E, Rapaport EL, Campbell TB, Koeppe JR, Wilson CC. CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology. 2007 Apr 25; 361(1):34-44.
    View in: PubMed
    Score: 0.040
  39. Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Rosenberg ES, Segal MR, Weidler J, Grant RM. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS. 2006 Oct 24; 20(16):2123-5.
    View in: PubMed
    Score: 0.040
  40. Koeppe JR, Campbell TB, Rapaport EL, Wilson CC. HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J Acquir Immune Defic Syndr. 2006 Feb 01; 41(2):140-8.
    View in: PubMed
    Score: 0.038
  41. Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006; 11(5):619-23.
    View in: PubMed
    Score: 0.038
  42. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis. 2005 Jul 15; 41(2):236-42.
    View in: PubMed
    Score: 0.036
  43. Campbell TB, Staskus KA, Folkvord J, White IE, Neid J, Zhang XQ, Connick E. Persistence of Kaposi sarcoma-associated herpesvirus (KSHV)-infected cells in KSHV/HIV-1-coinfected subjects without KSHV-associated diseases. J Infect Dis. 2005 Feb 01; 191(3):367-71.
    View in: PubMed
    Score: 0.035
  44. Neid JM, Schooley RT, Campbell TB. Stimulation of Kaposi's sarcoma-associated herpesvirus viremia during hematopoietic stem cell mobilization with filgrastim. Am J Hematol. 2004 Dec; 77(4):410-2.
    View in: PubMed
    Score: 0.035
  45. Connick E, Kane MA, White IE, Ryder J, Campbell TB. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis. 2004 Dec 15; 39(12):1852-5.
    View in: PubMed
    Score: 0.035
  46. Matiza T, Boyd KF, Lyall RA, Kwon DS, McGregor AM, Fiorillo S, Campbell TB, Borok M, Corleis B. Compartmentalized T cell profile in the lungs of patients with HIV-1-associated pulmonary Kaposi sarcoma. Medicine (Baltimore). 2021 Dec 23; 100(51):e28328.
    View in: PubMed
    Score: 0.028
  47. Connick E, Schlichtemeier RL, Purner MB, Schneider KM, Anderson DM, MaWhinney S, Campbell TB, Kuritzkes DR, Douglas JM, Judson FN, Schooley RT. Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion. J Infect Dis. 2001 Dec 01; 184(11):1465-9.
    View in: PubMed
    Score: 0.028
  48. Schooley RT, Mladenovic J, Sevin A, Chiu S, Miles SA, Pomerantz RJ, Campbell TB, Bell D, Ambruso D, Wong R, Landay A, Coombs RW, Fox L, Kamoun M, Jacovini J. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis. 2000 Jan; 181(1):148-57.
    View in: PubMed
    Score: 0.025
  49. Robertson KR, Oladeji B, Jiang H, Kumwenda J, Supparatpinyo K, Campbell TB, Hakim J, Tripathy S, Hosseinipour MC, Marra CM, Kumarasamy N, Evans S, Vecchio A, La Rosa A, Santos B, Silva MT, Montano S, Kanyama C, Firnhaber C, Price R, Marcus C, Berzins B, Masih R, Lalloo U, Sanne I, Yosief S, Walawander A, Nair A, Sacktor N, Hall C. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction. Clin Infect Dis. 2019 05 02; 68(10):1739-1746.
    View in: PubMed
    Score: 0.024
  50. Neff CP, Krueger O, Xiong K, Arif S, Nusbacher N, Schneider JM, Cunningham AW, Armstrong A, Li S, McCarter MD, Campbell TB, Lozupone CA, Palmer BE. Fecal Microbiota Composition Drives Immune Activation in HIV-infected Individuals. EBioMedicine. 2018 Apr; 30:192-202.
    View in: PubMed
    Score: 0.022
  51. Campbell TB, McDonald CK, Hagen M. The effect of structure in a long target RNA on ribozyme cleavage efficiency. Nucleic Acids Res. 1997 Dec 15; 25(24):4985-93.
    View in: PubMed
    Score: 0.021
  52. Erlandson KM, Fiorillo SP, Cardoso SW, Riviere C, Sanchez J, Hakim J, Kumarasamy N, Badal-Faesen S, Lalloo U, Kumwenda J, Campbell TB, Brown TT. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation. AIDS Res Hum Retroviruses. 2017 Sep; 33(9):929-934.
    View in: PubMed
    Score: 0.021
  53. Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B, Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K, Hakim J, Kumarasamy N, Campbell TB. Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis. 2017 03 15; 215(6):907-910.
    View in: PubMed
    Score: 0.020
  54. Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 01; 12(4):363-70.
    View in: PubMed
    Score: 0.020
  55. Labo N, Miley W, Benson CA, Campbell TB, Whitby D. Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy. AIDS. 2015 Jun 19; 29(10):1217-25.
    View in: PubMed
    Score: 0.018
  56. Campbell TB, Sullenger BA. Alternative approaches for the application of ribozymes as gene therapies for retroviral infections. Adv Pharmacol. 1995; 33:143-78.
    View in: PubMed
    Score: 0.017
  57. Letang E, Lewis JJ, Bower M, Mosam A, Borok M, Campbell TB, Naniche D, Newsom-Davis T, Shaik F, Fiorillo S, Miro JM, Schellenberg D, Easterbrook PJ. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS. 2013 Jun 19; 27(10):1603-13.
    View in: PubMed
    Score: 0.016
  58. Robertson K, Jiang H, Kumwenda J, Supparatpinyo K, Evans S, Campbell TB, Price R, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Montano S, Kanyama C, Faesen S, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Allen R, Housseinipour M, Amod F, Sanne I, Hakim J, Walawander A, Nair A. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis. 2012 Sep; 55(6):868-76.
    View in: PubMed
    Score: 0.015
  59. Robertson K, Kumwenda J, Supparatpinyo K, Jiang JH, Evans S, Campbell TB, Price RW, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Masih R, Santos B, Silva MT, Kumarasamy N, Walawander A, Nair A, Tripathy S, Kanyama C, Hosseinipour M, Montano S, La Rosa A, Amod F, Sanne I, Firnhaber C, Hakim J, Brouwers P. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol. 2011 Oct; 17(5):438-47.
    View in: PubMed
    Score: 0.014
  60. Flanigan TP, Campbell T, Harwell J, Kumarasamy N. The extraordinary hope of antiretroviral therapy in South Africa (even for patients with tuberculosis or kaposi sarcoma!). J Infect Dis. 2005 Feb 01; 191(3):321-3.
    View in: PubMed
    Score: 0.009
  61. Zhang Xq, Fitzpatrick L, Campbell TB, Badaro R, Schechter M, Melo Md, Brites C, Pedral-Sampaio D, Schooley RT. Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) in Brazil and Colorado. J Infect Dis. 1998 Nov; 178(5):1488-91.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)